November 14, 2016Acta Oncologica184 citationsOpen Access
View Full PaperPazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
Structured PICO
Does pazopanib show clinical activity in patients with advanced vascular sarcomas?
P
Population
Patients with advanced vascular sarcomas, including angiosarcoma (AS), hemangioendothelioma (HE), and intimal sarcoma (IS)
I
Intervention
Pazopanib
O
Outcome
Clinical activity
Pazopanib demonstrates promising clinical activity in advanced vascular sarcomas, warranting further evaluation.
Abstract
The activity of pazopanib in AS is comparable to its reported activity in other STS subtypes. In this study, the activity of pazopanib was similar in cutaneous/non-cutaneous and in radiation/non-radiation-associated AS. In addition, pazopanib showed promising activity in HE and IS, worthy of further evaluation.